INMB Share Price Performance
US$1.91
-3.17 (-62.40%)
76.1% undervalued intrinsic discount
US$8.00
Fair Value
Price US$1.91
AnalystHighTarget US$8.00
Fair ValueUS$8.00
Share Pricen/a
Can INmune Bio (NASDAQ:INMB) Afford To Invest In Growth?
Dec 09
INmune Bio, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
INMB Community Narratives
AN
Fair Value US$8 76.1% undervalued intrinsic discount
Rare Disease And Neuroinflammation Platforms Will Unlock Significant Long-Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Rare Disease And Neuroinflammation Platforms Will Unlock Significant Long-Term Upside Potential
Catalysts About INmune Bio INmune Bio develops platform immunotherapies that target inflammation and innate immunity to treat serious neurological, oncologic and rare diseases. What are the underlying business or industry changes driving this perspective?Read more
8
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$8
76.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
688.72% p.a.
Profit Margin
0.16%
Future PE
81.26x
Price in 2028
US$0.08
Trending Discussion
Recently Updated Narratives
AN
Rare Disease And Neuroinflammation Platforms Will Unlock Significant Long-Term Upside Potential
Fair Value: US$8 76.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
INmune Bio, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.88
- 100.00%
- -99,774.00%
- 0%
About INMB
- Founded
- 2015
- Employees
- 18
- CEO
- WebsiteView website
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
